Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...

A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Desaturation during the 6-minute walk test is a significant predictive factor for mortality in patients with idiopathic pulmonary fibrosis.

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...